Chemical formula: C₁₀H₁₆N₂O₄S₃ Molecular mass: 324.44 g/mol PubChem compound: 5284549
Dorzolamide is a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| S01EC03 | Dorzolamide | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EC Carbonic anhydrase inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TRUSOPT Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Dorzolamide is an active ingredient of these brands:
United States (US)
Albania (AL)
Australia (AU)Austria (AT)
Brazil (BR)
Croatia (HR)
Cyprus (CY)
Ecuador (EC)
Estonia (EE)Finland (FI)
France (FR)Germany (DE)
Hong Kong (HK)
Israel (IL)Italy (IT)
Japan (JP)Lithuania (LT)
Netherlands (NL)New Zealand (NZ)Nigeria (NG)Poland (PL)
Romania (RO)Singapore (SG)
South Africa (ZA)
Spain (ES)Tunisia (TN)Turkey (TR)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
